{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"Number of participants with a complete response. Complete Response (CR): Disappearance of clinical and radiological evidence of tumor.","groups":[{"description":"Cetuximab beginning weekly dose 400 mg/m\\^2 intravenous (IV), and 250 mg/m\\^2 weeks 2-6; Weekly Carboplatin AUC 2 and Paclitaxel 135 mg/m\\^2 for 6 courses.","id":"OG000","title":"Cetuximab + Carboplatin/Paclitaxel"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Study period of 3 Years","title":"Number of Participants With Complete Response","type":"PRIMARY","unitOfMeasure":"participants"}